Alnylam Signs Billion Dollar RNAi Deal With Roche
This article was originally published in The Pink Sheet Daily
Executive Summary
Best path to build value for shareholders is to maintain independent, focused and hungry biotech culture, Alnylam CEO tells “The Pink Sheet” DAILY.